Cite

HARVARD Citation

    Baldini, E. et al. (2020). Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung cancer. pp. 59-64. [Online]. 
  
Back to record